Caresyntax

Caresyntax sits close to the AI ready versus AI powered line the index uses elsewhere, and lands on the right side of it without clearing it comfortably. The substrate is operating room integration: video and audio management, device control, capture routing and EMR linked worklists, all of which are conventional OR integration functions that predate machine learning and would deliver value with none in the system.

The AI runs on top, and it is genuinely substantial, since analysing video, audio, images and connected device output together is a harder multimodal problem than anything else in this category attempts. The durable asset is nonetheless the installed base and the integration work across 4,000 operating rooms, not a model. Graded B rather than C because the analytics are differentiated rather than decorative, and rather than A because a buyer purchases the platform first and the intelligence second.

Nothing in the platform acts autonomously. It surfaces information to the surgical team live during a procedure and produces analysis afterwards, with clinicians retaining every decision. What is not published is how the intraoperative layer behaves under pressure: no disclosure was located on how real time prompts are presented, whether they can be suppressed, how alert burden is managed, or what happens when the system's read of a procedure diverges from the surgeon's.

Intraoperative decision support is a setting where a mistimed or unexplained prompt is itself a safety concern, and the absence of any published human factors position is the gap. Publishing the alerting and suppression design would move this to A.

The description stays at the level of proprietary software and AI applied to large volumes of video, audio, images, device, clinical and operational data. No model family, architecture or validation is disclosed, and no accuracy figure was located for any individual analytic.

The multimodal claim is the one most in need of substantiation, because combining audio and video inference in an acoustically chaotic room full of equipment is materially harder than analysing an endoscopic feed alone, and nothing published describes how well it works. Naming which analytics are model driven and which are rules over device telemetry would be the most useful single disclosure.

Nothing identifies any party in the chain: no model or model family, no foundation model provider, no hosting arrangement and no sub processor list was located in two passes, and the description stays at the level of proprietary software applied to large volumes of video, audio, images, device, clinical and operational data. Medical grade is a positioning claim rather than a disclosure. What the unnamed chain handles is unusually broad and unusually sensitive in combination.

Video and audio from inside an operating theatre sit alongside device telemetry and clinical data, so a single deployment holds the surgical field, the team's speech and the equipment record for every case, and none of those de identifies the way structured text does.

Audio is the category most likely to travel to a third party, because speech processing is commonly supplied rather than built, and nothing states whether any external service touches it or whether processing happens on premises. That question should be asked directly rather than inferred from the absence of a named partner, since several vendors in this index were found to use unnamed speech suppliers. Ask which analytics are model driven, whose models they are, where audio is processed, and for a sub processor list.

Real operational results exist and none of them reached this assessment through the vendor. A University of Iowa deployment analysing operating room video and audio is reported to have cut turnover by roughly 10 to 15 minutes on average, enough for an additional case per room per day, and to have surfaced lapses in prophylactic patient warming associated with postoperative infection risk.

A 2023 publication is reported to show cost reduction and quality of life improvement in colorectal surgery. Both reached this record through third party summaries rather than retrieved vendor or primary sources, so they are recorded as secondary sourced and warrant confirmation. Scale is substantial at more than two million procedures a year across 4,000 rooms, but the index rule that deployment volume does not substitute for evidence of benefit applies. Graded C on sourcing quality rather than on absence of results, and a retrieved primary citation would likely move this to B.

The audio capture is the part buyers underestimate. Caresyntax analyses sound from the operating room alongside video and device data, and an operating room microphone records the surgical team talking, including teaching, disagreement, error recognition and ordinary conversation that no one framed as a clinical record. That is simultaneously patient data and staff speech, and the index has treated the surveillance of named clinicians as a first order concern since the cybersecurity lane.

No vendor published statement was located on audio retention, whether speech is transcribed or only analysed acoustically, who inside an institution can replay it, or whether staff consent separately from patients. The platform is described as medical grade, which is a positioning claim rather than a stewardship disclosure. Publishing the audio handling policy would move this to B and is the disclosure this vendor most needs.

Converted from Not Rated after a second search, which reached material the first pass did not.

The company publishes a privacy notice stating that it complies with the European data protection regulation, the United States health privacy rule and the health information technology act that extended obligations directly to business associates. Naming that third instrument is a small but real signal, because it is the one that makes a vendor in this position directly liable rather than liable only through contract. Separately, the company's own implementation guidance tells prospective customers that finalising the business associate agreement and an information technology security agreement requires sustained work with their IT department, which confirms both artefacts exist as standard parts of a deployment.

One structural point to settle first. The company states it comprises a German entity and a United States entity. Which one contracts, and whether the other has access to United States patient data, determines both the business associate analysis and the transfer position, and neither is stated.

The more consequential questions concern where surgical data goes after capture, because this platform has unusually many onward paths and each needs its own basis. The company describes producing analytics for medical device companies, insurers and other ecosystem participants. It has announced a collaboration with a medical professional liability insurer under which insured surgeons integrate surgical video and real world evidence. And it has offered a practice building application through which surgeons share surgical content on consumer video platforms. Treatment, operational analytics, insurer analytics and public promotion are four different uses, and the last in particular is marketing rather than health care operations.

Establish which entity signs, what the agreement permits by way of secondary use and aggregation, and what basis covers any content that leaves the institution.

No SOC 2 Type II, HITRUST or ISO 27001 attestation was located and no trust center was found in retrieved material. The platform is described as medical grade and interoperable, and a Google Cloud partnership provides infrastructure assurance, but neither is an application level attestation.

For a European headquartered lineage operating across international markets, an ISO 27001 certificate would be the expected artefact and its absence from public materials is notable rather than damning. Given enterprise scale and insurer investors, the likelier explanation is that certifications exist and are not published, which is itself a finding: buyers should ask rather than assume in either direction.

No FDA clearance was located for the platform, and the position here is less settled than for the other vendors in this vein, which is why the grade is a C rather than a category non application B.

Caresyntax describes real time clinical decision support delivered to the care team during a procedure. Clinical decision support software sits in a regulatory grey zone whose boundaries have moved recently, with the FDA signalling in January 2026 a lighter touch on digital health and decision support products. Software that informs an intraoperative decision is a different regulatory proposition from software that summarises a case afterwards, and the company states no position on which of its analytics fall where.

Buyers should establish which specific analytics the vendor treats as non device decision support and on what reasoning, because that answer determines who carries the risk if a prompt delivered mid procedure is wrong.

This is the most consequential row on the record and it turns on who the customer is. Caresyntax states plainly that its insights serve insurance companies seeking to understand risk and devise more tailored policies, and its investor base includes the medical liability insurers ProAssurance and Relyens. That means performance data generated from a named surgeon's operations flows toward the parties who price that surgeon's malpractice cover.

The arrangement may well be aggregated and anonymised, and nothing located suggests otherwise, but nothing located confirms it either, and the disclosure a surgical department needs before signing is precisely that boundary: what leaves the institution, at what level of aggregation, and whether individual performance can be reidentified downstream.

The unadjusted benchmarking problem recorded against Theator applies here too, since comparative surgeon analytics without published risk adjustment for case mix penalise whoever accepts the hardest cases. Publishing the data sharing boundary with the insurance line of business would move this to B.

Two passes located no accuracy figure for any individual analytic, no validation methodology, no published limitations and no warranty, indemnity or remediation commitment, and the multimodal claim is the one most in need of substantiation because combining audio and video inference in an acoustically chaotic room full of equipment is materially harder than analysing a single endoscopic feed.

Nothing published describes how well it works, and naming which analytics are model driven and which are rules over device telemetry would be the single most useful disclosure this vendor could make, because those two carry entirely different assurance requirements. The audio capture is the part buyers most underestimate and it is the sharpest version of a shape this index has now recorded across four operating theatre and inpatient products.

An operating room microphone records the surgical team talking, and theatre conversation includes teaching, disagreement, real time error recognition and ordinary talk that nobody framed as a clinical record. A recording of a surgeon saying that something is wrong and correcting course is simultaneously the most clinically valuable signal in the room and the most professionally hazardous artefact the institution could hold.

Nothing published states whether speech is transcribed or only analysed acoustically, how long audio persists, who inside an institution can replay it, or whether staff consent separately from patients. Ask all four before deployment, and ask what a clinician can request be deleted.

Interoperability is a design principle here rather than a feature, and the vendor neutral positioning is meaningful in a market where operating room integration is dominated by device manufacturers selling into their own ecosystems. The platform integrates connected device output, controls equipment, manages video and audio routing, and links to the EMR for worklist creation, which is genuine bidirectional clinical system integration rather than an asserted connector list.

What is not published is which EHR systems are supported by name, how deep the write back goes beyond worklists, and whether device coverage spans the major surgical equipment vendors or a subset. Naming supported EHRs and device manufacturers would move this to A.

The architecture is described as edge to cloud, which is the correct shape for this problem: video and audio inference has to happen close to the operating room for latency and bandwidth reasons, with aggregation and analytics in the cloud, and naming that split is more disclosure than most peers offer. A Google Cloud partnership indicates the cloud layer.

What is missing is residency detail, which matters more than usual for a company operating across US and European markets, since operating room video and staff audio from an EU institution carry obligations that a US hosted analytics tier would complicate. Naming the regions and stating what stays on premise would move this to A.

No rate, unit or charging mechanism was located. Third party commentary describes an analytics as a service subscription model for the operating room, which is recorded as secondary sourced and unconfirmed. Two structural questions matter more here than the headline number.

The first is what the platform costs against what it displaces, since the operational business case rests on throughput gains such as an additional case per room per day, which is a savings linked framing the index scrutinises. The second is whether the multi customer model affects pricing, specifically whether a hospital's fee is offset by the value of its data to the device manufacturer and insurance lines of business. That is a fair question to ask directly and a buyer is entitled to a plain answer.

The broadest surgical footprint in the index. Software runs in more than 4,000 operating rooms worldwide, supports over 30,000 surgical professionals and touches more than two million procedures a year, across an international rather than US only base. Because the platform instruments the room rather than a specific procedure type, coverage is not confined to endoscopic or robotic cases the way video only analytics are, which is a genuine structural advantage over the rest of this vein.

The buyer set is equally broad and spans hospitals, surgeons, medical device manufacturers and insurers. The caveat that keeps this honest rather than lowering it: breadth of installation is not the same as depth of analytic coverage per specialty, and no published breakdown of which analytics are validated for which procedure types was located.